○Joachim Aerts1, Luis Paz-Ares2, Carole Helissey3, Frederico Cappuzzo4, Gilles Quere5, Dariusz Kowalski6, Jose Carlos Benitez7, Florian Guisier8, Benjamin Besse9, Gadgeel Shirish10, Wehler Thomas11, Ignacio Gil-Bazo12, Michael J. Chisamore13, Cem Gorgun14, Ilhan Celik15, Marie Holst Morch16, Patricia Garrido Castro17, Teng Jin Ong18, Enriqueta Felip19
(1.Erasmus MC, Rotterdam, Netherlands, 2.Hospital Universitario 12 de Octubre, Madrid, Spain, 3.Military Hospital Begin, Saint-Mand?, France, 4.IFO Regina Elena, Rome, Italy, 5.Hopital Morvan CHU de Brest, Brest, France, 6.The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, 7.Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Biomedical Research Institute of M?laga（IBIMA BIONAND Platform）, M?laga, Spain, 8.Normandie Univ, UNIROUEN, LITIS Lab QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, F-76000 Rouen, France, 9.Gustave Roussy, Villejuif, France, 10.Henry Ford Cancer Institute, Detroit, USA, 11.Universitatsklinik Gie?en und Marburg, Standort Gie?en, Marburg, Germany, 12.Fundacion Instituto Valenciano de Oncologia, Valencia, Spain, 13.Merck ＆ Co., Inc., Rahway, USA, 14.BioNTech US Inc., Cambridge, USA, 15.BioNTech SE, Mainz, Germany, 16.Genmab, Copenhagen, Denmark, 17.Genmab, Utrecht, Netherlands, 18.Genmab, Plainsboro, USA, 19.Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain)
アンコール演題
